MX366342B - Forma solida de un derivado de dihidro-pirido-oxazina. - Google Patents

Forma solida de un derivado de dihidro-pirido-oxazina.

Info

Publication number
MX366342B
MX366342B MX2015006650A MX2015006650A MX366342B MX 366342 B MX366342 B MX 366342B MX 2015006650 A MX2015006650 A MX 2015006650A MX 2015006650 A MX2015006650 A MX 2015006650A MX 366342 B MX366342 B MX 366342B
Authority
MX
Mexico
Prior art keywords
pyrido
dihydro
solid form
oxazine derivative
forms
Prior art date
Application number
MX2015006650A
Other languages
English (en)
Other versions
MX2015006650A (es
Inventor
Kammertoens Karen
Soldermann Nicolas
Zecri Frédéric
Hurth Konstanze
Kalis Christoph
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51019963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366342(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015006650A publication Critical patent/MX2015006650A/es
Publication of MX366342B publication Critical patent/MX366342B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con una forma cristalina anhidra de (1,1- dioxo-hexahidro-1-lambda*6*tiopiran-4il)-{(S)-3-[1-(6-metoxi -5-metil-piridin-3-iI)-2,3-dihidro-1H-pirido[3,4-b][1,4]oxazin-7- iloxi]-pirrolidin-1-il}metanona; composiciones farmacéuticas y combinaciones incluyendo estas formas, así como a métodos de uso de estas formas, incluyendo sus composiciones farmacéuticas y combinaciones para el tratamiento de enfermedades.
MX2015006650A 2012-11-26 2013-11-26 Forma solida de un derivado de dihidro-pirido-oxazina. MX366342B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GC201222895 2012-11-26
IR1391307213 2012-12-04
PCT/IB2013/060412 WO2014102630A1 (en) 2012-11-26 2013-11-26 Solid form of dihydro-pyrido-oxazine derivative

Publications (2)

Publication Number Publication Date
MX2015006650A MX2015006650A (es) 2015-08-10
MX366342B true MX366342B (es) 2019-07-05

Family

ID=51019963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006650A MX366342B (es) 2012-11-26 2013-11-26 Forma solida de un derivado de dihidro-pirido-oxazina.

Country Status (22)

Country Link
EP (1) EP2928896B1 (es)
KR (1) KR102184069B1 (es)
CN (1) CN104870451B (es)
AU (1) AU2013368997B8 (es)
BR (1) BR112015009870A2 (es)
CA (1) CA2891521A1 (es)
CL (1) CL2015001409A1 (es)
CY (1) CY1119702T1 (es)
DK (1) DK2928896T3 (es)
GT (1) GT201500124A (es)
IL (1) IL238889B (es)
MX (1) MX366342B (es)
NZ (1) NZ706865A (es)
PE (1) PE20150946A1 (es)
PH (1) PH12015501052A1 (es)
PL (1) PL2928896T3 (es)
PT (1) PT2928896T (es)
SG (1) SG11201503410VA (es)
TN (1) TN2015000128A1 (es)
TW (1) TW201422625A (es)
WO (1) WO2014102630A1 (es)
ZA (1) ZA201502350B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2794600T3 (pl) 2011-12-22 2018-06-29 Novartis Ag Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
FI3837263T3 (fi) 2018-08-13 2024-09-03 Hoffmann La Roche Uusia heterosyklisiä yhdisteitä monoasyyliglyserolilipaasin estäjinä
JP7444882B2 (ja) 2018-11-22 2024-03-06 エフ． ホフマン－ラ ロシュ アーゲー 新規の複素環化合物
PE20220565A1 (es) 2019-09-12 2022-04-13 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
CN1100778C (zh) 1995-07-06 2003-02-05 诺瓦蒂斯有限公司 吡咯并嘧啶及其制备方法
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
EP0938597B1 (en) 1996-09-06 2003-08-20 Obducat Aktiebolag Method for anisotropic etching of structures in conducting materials
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
DE59712968D1 (de) 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
IL138113A0 (en) 1998-02-25 2001-10-31 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto and analogues thereof
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ES2332770T3 (es) 2000-11-07 2010-02-12 Novartis Ag Derivados de indolilmaleimida como inhibidores de la proteina quinasa c.
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
PL376844A1 (pl) 2002-12-09 2006-01-09 The Board Of Regents Of The University Of Texas System Sposoby selektywnego hamowania kinazy tyrozynowej 3 z grupy Janus (JAK3)
CN100465173C (zh) 2004-01-12 2009-03-04 西托匹亚研究有限公司 选择性激酶抑制剂
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP2009507072A (ja) * 2005-09-07 2009-02-19 ラボラトワール セローノ ソシエテ アノニム 子宮内膜症の処置のためのｐｉ３ｋ阻害剤
GB0620059D0 (en) * 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
PL2794600T3 (pl) * 2011-12-22 2018-06-29 Novartis Ag Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów

Also Published As

Publication number Publication date
AU2013368997A1 (en) 2015-04-30
KR102184069B1 (ko) 2020-11-30
IL238889A0 (en) 2015-07-30
NZ706865A (en) 2016-04-29
EP2928896A1 (en) 2015-10-14
TN2015000128A1 (en) 2016-10-03
CA2891521A1 (en) 2014-07-03
IL238889B (en) 2021-03-25
AU2013368997B2 (en) 2015-09-24
CN104870451B (zh) 2017-07-07
AU2013368997B8 (en) 2015-10-08
BR112015009870A2 (pt) 2017-12-05
AU2013368997A8 (en) 2015-10-08
GT201500124A (es) 2016-03-01
PT2928896T (pt) 2017-10-25
PH12015501052A1 (en) 2015-07-27
SG11201503410VA (en) 2015-05-28
EP2928896B1 (en) 2017-07-19
TW201422625A (zh) 2014-06-16
WO2014102630A1 (en) 2014-07-03
PL2928896T3 (pl) 2018-01-31
KR20150091047A (ko) 2015-08-07
CY1119702T1 (el) 2018-06-27
HK1209419A1 (en) 2016-04-01
CL2015001409A1 (es) 2015-07-24
MX2015006650A (es) 2015-08-10
CN104870451A (zh) 2015-08-26
ZA201502350B (en) 2017-08-30
DK2928896T3 (da) 2017-11-06
PE20150946A1 (es) 2015-06-28

Similar Documents

Publication Publication Date Title
CA2871471C (en) Dna-pk inhibitors
MY193728A (en) Muscarinic receptor agonists
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
IN2014CN03597A (es)
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
MY191352A (en) Aldosterone synthase inhibitors
PH12017500595B1 (en) Aldosterone synthase inhibitors
IN2012DN03846A (es)
PH12015500310A1 (en) Pyrrolopyrazoles as n-type calcium channel blockers
PH12015501052A1 (en) Solid form of dihydro-pyrido-oxazine drivative
GB201209015D0 (en) Novel compounds
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
PH12015500314B1 (en) Cyclopentylpyrazoles as n-type calcium channel blockers
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
EA201591023A1 (ru) Твердая форма производного дигидропиридооксазина
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors
MX2014002343A (es) Inhibidores de parp.

Legal Events

Date Code Title Description
FG Grant or registration